WeightWatchers to offer compounded version of Novo Nordisk's weight-loss drug
WeightWatchers said on Tuesday it would offer a compounded version of Novo Nordisk's popular obesity drug Wegovy as part of its weight-management programs. Soaring demand for weight-loss drugs such as Wegovy and Eli Lilly's Zepbound,
Sanders, Novo Nordisk CEO clash over Ozempic, Wegovy drug prices
The CEO of Novo Nordisk wouldn’t commit to lowering the prices of Ozempic and Wegovy during a Senate hearing Tuesday, despite repeatedly being pressed by Sen. Bernie Sanders (I-Vt.), chair of the
Novo Nordisk's Ozempic, Regeneron/Sanofi's Dupixent set to advance in top drug sales
AbbVie Humira, Pfizer/BioNTech COVID-19 shot may not make top 10 pharma drugs in 2024, with Novo Nordisk Ozempic and Regeneron/Sanofi Dupixent taking their place. Read more here.
Novo Nordisk settles US patent fight with Viatris over Ozempic
Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and Wegovy, the companies told a U.S. Patent and Trademark Office tribunal.
Novo Nordisk (NYSE:NVO) and Viatris Settle Patent Dispute for Weight-Loss Drugs
Novo Nordisk ($NVO) and Viatris ($VTRS) have agreed to settle a dispute over patents for Novo’s weight-loss drugs, Ozempic and Wegovy, according
Novo Nordisk, Viatris settle patent dispute over Ozempic, Wegovy: report
Novo Nordisk (NVO) and Viatris (NASDAQ:VTRS) have reportedly reached an agreement in their dispute over U.S. patents protecting Novo’s popular weight-loss drugs Wegovy and Ozempic. The companies announced the settlement in a joint filing on Friday made with the U.
BioSpace6h
Novo, Viatris Settle Ozempic Patent Row
Alongside the settlement, Novo and Viatris have asked the U.S. Patent and Trademark Office to terminate its review of the ...
FiercePharma1d
Amid GLP-1 craze, Novo and Mylan ink patent settlement in Ozempic case
With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their ...
Novo Nordisk Just Committed More Than $1.1 Billion to Make the Next Ozempic, but Is the Stock a Buy?
In mid-September, Novo Nordisk inked a pair of deals worth a total of more than $1.1 billion in research and development (R&D ...
Mass. to play a key role as Novo Nordisk grows beyond Ozempic
Novo Nordisk says Massachusetts plays a key role in its bid to expand beyond its historic focus as a diabetes and obesity ...
Novo Nordisk's diabetes drug Ozempic may lower the risk of opioid overdoses, study says
The results suggest Ozempic could potentially become a new alternative treatment for opioid use disorder, which could help ...
As Kourtney Kardashian jumps into market, do Ozempic alternatives work?
Expensive weight-loss drugs like Ozempic, Wegovy are often in short supply. Should we turn to OTC supplements that promise ...
Novo Nordisk Is Still a Buy, Analysts Say. Slowing Growth for Ozempic and Wegovy Isn’t a Problem.
The company is expected to present critical results from a trial of its CagriSema weight-loss injection in the fourth quarter ...
tyla6h
Sharon Osbourne revealed side-effects of Ozempic after admitting to using drug
Sharon Osbourne has opened up about using the popular weight loss injection Ozempic, including the little-known side effects.